- Report
- July 2024
- 70 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- April 2024
- 160 Pages
Global
From €4742EUR$4,969USD£3,973GBP
- Report
- June 2024
- 183 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- May 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP
- Report
- May 2024
- 93 Pages
Global
From €14311EUR$14,995USD£11,991GBP
- Report
- June 2024
- 140 Pages
Asia Pacific
From €3692EUR$3,869USD£3,094GBP
- Report
- June 2024
- 140 Pages
Latin America
From €3692EUR$3,869USD£3,094GBP
- Report
- June 2024
- 140 Pages
Europe
From €3692EUR$3,869USD£3,094GBP
- Report
- November 2023
- 175 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- June 2021
- 50 Pages
China
From €2481EUR$2,600USD£2,079GBP
- Report
- September 2022
- 30 Pages
Global
From €2625EUR$2,750USD£2,199GBP
- Report
- February 2024
- 181 Pages
Europe
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 176 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 160 Pages
Middle East, Africa
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 90 Pages
Europe
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
Latin America
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
Germany
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
Italy
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
Oman
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
Egypt
From €4533EUR$4,750USD£3,798GBP

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used as an anti-obesity drug. It is a long-acting analogue of human GLP-1, a hormone that is released in response to food intake. Liraglutide works by stimulating the release of insulin and suppressing appetite. It is typically prescribed as an adjunct to diet and exercise for the treatment of obesity. It is also used to treat type 2 diabetes.
Liraglutide is available in both injectable and oral formulations. The injectable form is administered subcutaneously once daily, while the oral form is taken once daily with food. Common side effects of liraglutide include nausea, vomiting, diarrhea, and abdominal pain.
Several companies are involved in the liraglutide market, including Novo Nordisk, Eli Lilly, Sanofi, and Merck. Show Less Read more